GLPBio

Tunicamycin Mixture

Catalog No.: GC16738Purity:>95.00%
Tunicamycin Mixture is a mixture of homologous nucleoside antibiotics that inhibits N-glycosylation and blocks GlcNAc phosphotransferase (GPT).

Products are for research use only. Not for human use. We do not sell to patients.


Tunicamycin Mixture
Cas No.: 11089-65-9
1mgIn Stock
$43.00
1
5mgIn Stock
$117.00
1
10mgIn Stock
$210.00
1

Citations

12 publicationsPublications from researchers using this product
IF 13

Description

Tunicamycin Mixture is a mixture of homologous nucleoside antibiotics that inhibits N-glycosylation and blocks GlcNAc phosphotransferase (GPT)[1]. Tunicamycin Mixture can induce cellular endoplasmic reticulum (ER) stress and lead to blockage of DNA synthesis and G1 phase arrest [2]. Tunicamycin Mixture inhibits Gram-positive bacteria, yeast, fungi and viruses and has anti-cancer activity [3].

In vitro, pretreatment of RAW264.7 cells with Tunicamycin Mixture (0.5μg/ml) for 2h significantly reduced LPS-induced nitrite production and weakened the expression of iNOS and COX-2 mRNA and protein[4]. Tunicamycin Mixture (1-20μg/ml) treated prostate cancer PC-3 cells for 24-96h, dose-dependently reduced cell viability, blocked the formation of N-glycosylation in proteins and induced endoplasmic reticulum stress [5] .

In vivo, Tunicamycin Mixture (1mg/kg) treated mice via intraperitoneal injection, significantly increased hepatic triglyceride accumulation, inhibited hepatic lipoprotein secretion, and reduced blood glucose levels and liver glycogen content [6]. The administration of a Tunicamycin mixture (2μg) via intratracheal delivery in a neutrophilic asthma model (OVALPS-OVA mice) increased the protein expression levels of endoplasmic reticulum stress markers and inflammatory cytokines, leading to a more severe asthma phenotype in the mice [7].

References:
[1] Hsu J L, Chiang P C, Guh J H. Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2009, 380: 373-382.
[2] Han C, Jin L, Mei Y, et al. Endoplasmic reticulum stress inhibits cell cycle progression via induction of p27 in melanoma cells[J]. Cellular signalling, 2013, 25(1): 144-149.
[3] Pałasz A, Cież D. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications[J]. European journal of medicinal chemistry, 2015, 97: 582-611.
[4] Kim S Y, Hwang J S, Han I O. Tunicamycin inhibits Toll-like receptor-activated inflammation in RAW264. 7 cells by suppression of NF-κB and c-Jun activity via a mechanism that is independent of ER-stress and N-glycosylation[J]. European journal of pharmacology, 2013, 721(1-3): 294-300.
[5] Guha P, Kaptan E, Gade P, et al. Tunicamycin induced endoplasmic reticulum stress promotes apoptosis of prostate cancer cells by activating mTORC1[J]. Oncotarget, 2017, 8(40): 68191.
[6] Feng B, Huang X, Jiang D, et al. Endoplasmic reticulum stress inducer tunicamycin alters hepatic energy homeostasis in mice[J]. International journal of molecular sciences, 2017, 18(8): 1710.
[7]Guo Q, Li H, Liu J, et al. Tunicamycin aggravates endoplasmic reticulum stress and airway inflammation via PERK-ATF4-CHOP signaling in a murine model of neutrophilic asthma[J]. Journal of Asthma, 2017, 54(2): 125-133.

Protocol

Cell experiment [1]:

Cell lines

RAW264.7 cells

Preparation method

RAW264.7 cells were pre-treated with 0.5μg/ml Tunicamycin Mixture for 2h and then incubated with LPS for 18h.

Reaction Conditions

0.5μg/ml; 2 h

Applications

Tunicamycin Mixture significantly reduced LPS-induced nitrite production/release and attenuated iNOS and COX-2 mRNA and protein expression.

Animal experiment [2]:

Animal models

C57BL/6 male mice

Preparation method

The mice were randomly divided into 2 groups according to similar average body weight and blood glucose level. One group were injected intraperitoneally with 1mg/kg Tunicamycin Mixture or vehicle. The body weight and blood glucose level at fed state were measured 24 h after injection. Later, mice were euthanized using carbon dioxide, followed by cervical dislocation.

Dosage form

1mg/kg;i.p.

Applications

Tunicamycin Mixture treatment for 24 hours significantly increased liver triglyceride accumulation, inhibited liver lipoprotein secretion, and reduced blood sugar levels and liver glycogen content.

References:

[1] Kim S Y, Hwang J S, Han I O. Tunicamycin inhibits Toll-like receptor-activated inflammation in RAW264. 7 cells by suppression of NF-κB and c-Jun activity via a mechanism that is independent of ER-stress and N-glycosylation[J]. European journal of pharmacology, 2013, 721(1-3): 294-300.

[2] Feng B, Huang X, Jiang D, et al. Endoplasmic reticulum stress inducer tunicamycin alters hepatic energy homeostasis in mice[J]. International journal of molecular sciences, 2017, 18(8): 1710.

Product Documents

Purity:>95.00%Appearance:A solid

Biological Data

1 / 3

Chemical Properties

CAS No.
11089-65-9
Molecular Formula
C39H64N4O16 (for Tunicamycin VII)
Molecular Weight
845.0
Solubility
DMF: 20 mg/ml DMSO: 20 mg/ml DMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for Tunicamycin Mixture

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%